Flynn Pharma was fined £5.2 million for its part in charging “excessive and unfair” prices for epilepsy drug phenytoin sodium, the government’s competition watchdog announced yesterday (December 7).
The distributor warned that if left unchallenged, the Competition and Markets Authority's (CMA) decision would “stunt investment in generics, eventually leading to a reduction in supply and less choice for doctors and patients”.
Flynn vowed to appeal the decision in court, arguing it is “based on a wholly flawed understanding of the UK pharmaceutical market”, it said in a statement yesterday.
The CMA has made “a serious error” in its decision, the distributor added, one that could impact future investment in, and the availability of, generics in the UK.
Chief executive David Fakes said it “beggars belief” that the CMA chose to punish Flynn, along with Pfizer, for selling phenytoin capsules – which he claimed are sold at a “significant discount” to the equivalent, phenytoin tablets.
“Phenytoin tablets are used for an identical purpose and for the last nine years have been sold at a price negotiated and accepted by the Department of Health," he stressed.
“It makes little sense that the CMA has chosen to penalise the cheaper therapy supplier.”
He added that it is “a matter of common interest” for the decision to be overturned and Flynn is consulting its legal team to prepare an appeal.